JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2022. Vol. 67. № 1
Hyperthermic Methods in Conservative
and Palliative Treatment of Oncological Patients.
Part 1. Loco-Regional Hyperthermia
O.K. Kurpeshev1, J. Van Der Zee2
1 Siberian Scientific Research Institute of Hyperthermia, Novosibirsk, Russia.
2 Erasmus Medical Centre, Cancer Institute, Rotterdam, The Netherlands
Contact person: Orazakhmet Kerimbaevich Kurpeshev, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
CONTENTS
The analysis of the results of conservative and palliative treatment of cancer patients with the use of loco-regional hyperthermia (LRHT) alone or in combination with various methods of anticancer therapy was carried out. The data obtained showed that LRHT significantly increases the immediate results of radiation and / or chemotherapy, has a pronounced palliative effect, and in some cases provides long-term local control. In incurable patients who have exhausted the "limit" of chemotherapy and / or radiation therapy, its use for palliative purposes is also possible in mono-mode.
Keywords: review, loco-regional hyperthermia, conservative therapy, palliative therapy, thermochemotherapy, thermoradiation therapy
For citation: Kurpeshev OK, Van Der Zee J. Hyperthermic Methods in Conservative and Palliative Treatment of Oncological Patients.
Part 1. Loco-Regional Hyperthermia. Medical Radiology and Radiation Safety. 2022;67(1):87–98.
DOI: 10.12737/1024-6177-2022-67-1-87-98
References
1. Состояние онкологической помощи населению России в 2018 году (под редакцией А.Д. Каприна, В.В. Старинского, Г.В. Петровой). М.: МНИОИ им П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2019. 236 стр. http://www.oncology.ru/service/statistics/[The state of oncological assistance to the population of Russia in 2018 (edited by A. Kaprin, VV. Starinsky and GV. Petrova). Moscow: Herzen Moscow Research Institute – a branch of the Federal State Budget Scientific Research Center for Radiology of the Russian Ministry of Health. 2019. 236 pp. (In Russ.)]. http://www.oncology.ru/service/statistics/]
2. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019. E1-E20. September 27. DOI: https://doi.org/10.1001/jamaoncol.2019.2996.
3. Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson AB, Mariotto A, Lake AJ, Wilson R, Sherman RL, Anderson RN, Henley SJ, Kohler BA, Penberthy L, Feuer EJ, Weir HK. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival. J. of the National Cancer Institute. 2017;109(9):djx030. DOI: 10.1093/jnci/djx030.
4. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Atlanta: American Cancer Society, 2016. Inc. No.865016.
5. Nahum AE. Converting Dose Distributions into Tumour Control Probability Radiation Dose in Radiotherapy from Prescription to Delivery. IAEA, A-1400 Vienna, Austria. 1996: 27-40.
6. Орлова Р.В., Вайзьян Р.И., Иванова А.К., Тихонова Е.К., Зорина Е.Ю. Химиотерапия злокачественных опухолей: проблемы и перспективы // Вопросы онкологии. 2015. № 2(61). С. 244-251. [Orlova RV, Vaizyan RI, Ivanova AK, Tikhonova EK, Zorina EY. Chemotherapy of Malignant Tumors: Problems and Prospects. Problems in Oncology. 2015;61(2):244-51. (In Russ.).]
7. Поддубная И.В., Орел Н.Ф. Побочные реакции и осложнения противоопухолевой лекарственной терапии. Руководство по химиотерапии опухолевых заболеваний (под ред. Н.И. Переводчиковой и В.А.Горбуновой). М.: Практическая медицина, 2011:425-446. [Poddubnaya IV, Oryol NF. Adverse Reactions and Complications of Antitumor Drug Therapy. Guidelines for the Chemotherapy of Tumor Diseases (ed. NI. Perevodchicova and VA. Gorbunova). Moskow. Practical medicine. 201:425-46. (In Russ.)]
8. Чубенко ВА. Осложнения таргетной терапии // Практическая онкология. 2010. № 3(11). С. 192-202. [Chubenko VA. Complications of Targeted Therapy. Practical Oncology. 2010;11(3):192-202. (In Russ.)]
9. De Angelis CD, Fontanarosa PB. Prescription Drugs, Products Liability, and Preemption of Tort Litigation. JAMA. 2008;300(16):1939-41.
10. Ставровская А.А, Генс Г.П. Некоторые новые аспекты исследований множественной лекарственной устойчивости опухолевых клеток // Успехи молекулярной онкологии. 2014. № 1(1). С. 5-11. doi:10.17650/2313-805X.2014.1.1.5-11.[Stavrovskaya AA, Gens GP. Some New Aspects of Studies of Multidrug Resistance of Tumor Cells. Advances in Molecular Oncology. 2014;1(1):5-11. (In Russ.)]. DOI: 10.17650 / 2313-805X.2014.1.1.5-11.
11. Трякин А.А., Федянин М.Ю., Покатаев И.А. 20 лет таргетной терапии солидных опухолей. Успехи и неудачи // Практическая онкология. 2018. № 3(19). С. 183-199. [Tryakin AA, Fedyanin MYu, Pokataev IA. 20 Years of Targeted Therapy of Solid Tumors. Success and Failure. Practical Oncology. 2018;19(3):183-99. (In Russ.)]
12. Zafar SY, Abernethy AP. Financial Toxicity, Part I: A New Name For A Growing Problem. Oncology (Williston Park). 2013;27(2):80-1.
13. Cheng Y, Weng S, Yu L, Zhu N, Yang M, Yuan Y. The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors. Integrative Cancer Therapies. 2019;18:1-11. DOI 10.1177/1534735419876345.
14. Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизмы развития и пути преодоления химиорезистентности опухолей. Часть 4. Экспериментальные основы и практические результаты применения общей гипертермии в лечении химиорезистентных опухолей // Российский онкологический журнал. 2003. № 3. С. 50-53. [Kurpeshev OK, Tsyb AF, Mardynsky YS, Berdov BA. Mechanisms of development and ways of overcoming the chemoresistance of tumors. Part 4. Experimental foundations and practical results of the use of general hyperthermia in the treatment of chemoresistant tumors. Russian Journal of Oncology. 2003;3:50-3. (In Russ.).]
15. Курпешев О.К, Ван дер Зее Я., Кавагнаро М. Гипертермия опухолей глубокой локализации: возможности ёмкостного метода // Медицинская радиология и радиационная безопасность. 2019;64(4):64–75. DOI: 10.12737/1024-6177-2019-64-4-64-75. DOI: 10.12737 / 1024-6177-2019-64-4-64-75. [Kurpeshev OK, Van der Zee J, Kavagnaro M. Hyperthermia of Tumors of Deep Localization: Possibilities of the Capacitive Method. Medical Radiology and Radiation Safety. 2019;64(4):64-75. (In Russ.). DOI: 10.12737 / 1024-6177-2019-64-4-64-75]
16. Van der Heijden AG, Dewhirst MW. Effects of Hyperthermia in Neutralizing Mechanisms of Drug Resistance in Non-Muscleinvasive Bladder Cancer. Int J Hyperthermia. 2016;32(4):434-45. http://dx.doi.org/10.3109/ 02656736.2016.1155761
17. Курпешев ОК. Закономерности радиосенсибилизирующего и повреждающего эффектов гипертермии на нормальные и опухолевые ткани. Автореф. дисс. докт. мед. наук. Обнинск, 1989. 35 с. [Kurpeshev OK. Patterns of the radiosensitizing and damaging effects of hyperthermia on normal and tumor tissues. Author’s abstract. diss. PhD, MD. Obninsk, 1989. 35 pp. (In Russ.)]
18. Панкратов В.А., Андреев В.Г., Рожнов В.А., Гулидов И.А., Барышев В.В., Буякова М..Е, Вдовина С.Н., Курпешев О.К., Подлесных Н.И. Одновременное применение химио- и лучевой терапии при самостоятельном консервативном и комбинированном лечении больных местно-распространенным раком гортани и гортаноглотки // Сибирский онкологический журнал. 2007. № 1. С. 18-22. [Pankratov VA, Andreev VG, Rozhnov VA. Gulidov IA, Baryshev VV, Buyakova ME. Vdovina SN, Kurpeshev OK, Podlesnykh NI. Simultaneous Use of Chemotherapy and Radiation Therapy in Independent Conservative and Combined Treatment of Patients with Locally Advanced Cancer of the Larynx and Laryngopharynx. Siberian J. Oncology. 2007;1:18-22. (In Russ.).]
19. Van der Zee J, Vujaskovic Z, Kondo M, Sugahara T. Part I. Clinical Hyperthermia. The Kadota Fund International Forum 2004 − Clinical Group Consensus. Int J Hyperthermia. 2008;24(2):111-22.
20. Курпешев О.К., van der Zee J. Локорегионарная гипертермия злокачественных опухолей − методики, термометрия, аппаратура // Медицинская радиология и радиационная безопасность. 2017. 5(62). С. 52-63. DOI: 10.12737/article_59f30321207ef4.88932385. [Кurpeshev ОК, van der Zee J. Locoregional Hyperthermia of Malignant Tumors: Methods, Thermometry, Machines. Medical Radiology and Radiation Safety. 2017;62(5):52-63. (In Russ.). DOI: 10.12737/article_59f303 21207ef4.88932385]
21. Kouloulias V, Triantopoulou S, Vrouvas J, Gennatas K, Ouzounoglou N, Kouvaris J, Karaiskos P, Aggelakis P, Antypas C, Zygogianni A, Papavasiliou K, Platoni K, Kelekis N. Combined Chemoradiotherapy with Local Microwave Hyperthermia for Treatment of T3N0 Laryngeal Carcinoma: a Retrospective Study with Long-Term Follow-Up. Acta Otorhinolaryngol Ital. 2014;34(3):167-73. PMCID: PMC4035838.
22. Zhu H, Huo X, Chen L. Wang H, Yu H. Clinical Experience with Radio- Chemo- and Hyperthermotherapy Combined Trimodality on Locally Advanced Esophageal Cancer. Molecular and Clinical Oncology. 2013;1:1009-12. DOI: 10.3892/mco.2013.161.
23. Oldenborg S, van Os RM, Van Rij CM, Crezee J, van de Kamer JB, Rutgers E, Geijsen ED, Zum vörde sive vörding PJ, Koning CC, Van tienhoven G. Elective Re-Irradiation and Hyperthermia Following Resection of Persistent Locoregional Recurrent Breast Cancer: A Retrospective Study. Int J Hyperthermia 2010;26(2):136-44.
24. Oldenborg S, Griesdoorn V, van Os R, Kusumanto YH, Oei BS, Venselaar JL, Geijsen ED, Zum vörde sive vörding PJ, Koning CC, Van tienhoven G. Reirradiation and Hyperthermia for Irresectable Locoregional Recurrent Breast Cancer in Previously Irradiated Area: Size Matters. Radiother Oncol. 2015;117:223-28.
25. Oldenborg S, Rasch CRN, van Os R, Kusumanto YH, Oei BS, Venselaar JL, Heymans MW, ZumVörde Sive Vörding PJ, Crezee H, van Tienhoven G. Reirradiation + Hyperthermia for Recurrent Breast Cancer en Cuirasse. Strahlentherapie und Onkologie. 2018;194:206-14. https://doi.org/10.1007/s00066-017-1241-1247.
26. Linthorst M, van Geel AN, Baaijens M, Ameziane A, Ghidey W, van Rhoon GC, van der Zee J. Re-Irradiation and Hyperthermia After Surgery for Breast Cancer. Radiother. Oncol. 2013;109:188-93.
27. Linthorst M, Baaijens M, Wiggenraad R. Creutzberg C, Ghidey W, van Rhoon GC, van der Zee J. Local Control Rate after the Combination of Reirradiation and Hyperthermia for Irresectable Recurrent Breast Cancer: Results in 248 Patients. Radiother. Oncol. 2015;117:217-22.
28. Notter M, Thomsen AR, Nitsche M, Hermann RM, Wol HA, Habl G, Münch K, Grosu A-L, Vaupel P. Combined wIRA-Hyperthermia and Hypofractionated Re-Irradiation in the Treatment of Locally Recurrent Breast Cancer: Evaluation of Therapeutic Outcome Based on a Novel Size Classification. Cancers. 2020;12(3):606-20. DOI: 10.3390/cancers12030606.
29. Linthorst M, van Rhoon GC, van Geel AN, Baaijens M, Ghidey W, Broekmeyer-Reurink MP, van der Zee J. The Tolerance of Reirradiation and Hyperthermia in Breast Cancer patients with reconstructions. Int. J. Hyperthermia. 2012;28(3):267-77. DOI: 10.3109/02656736.2012.663951.
30. Roesch M, Mueller-Huebenthal B. Review: The Role of Hyperthermia in Treating Pancreatic Tumors. Indian J Surg Oncol. 2015 March; 6(1):75–81. DOI: 10.1007/s13193-014-0316-5.
31. Yanai Y, Yasoshima T, Fukui R, Shishido T, Ezoe E, Furuta Y, Morosawa H, Miya Y, Sato Y, Kondo M. Retrospective Analysis of Hyperthermia Therapy Y. in 47 case of Unresectable Pancreatic Cancer. The 6th Asian Congress of Hyperthermic Oncology & The 31st Japanese Congress of Thermal Medicine at Fukui City, Japan. September 5 (Fri.) − 6 (Sat.). 2014:146. Абстракт GSJ10.
32. Hetzel FW, Mattiello J. Interactions of Hyperthermia with Other Modalities. Medical Physics Monograph. Biological, Physical and Clinical Aspects of Hyperthermia (editors: Paliwal BR, Hetzel FW, Dewhirst MW). Am. Inst. Phys. 1987;16:30–56 (cit. according to [16]).
33. Franckena M, De Wit R, Ansink AC, Notenboom A, Canters RAM, Fatehi D, Van Rhoon GC, Van Der Zee J. Weekly Systemic Cisplatin Plus Locoregional Hyperthermia: An Effective Treatment for Patients with Recurrent Cervical Carcinoma in a Previously Irradiated Area. Int J Hyperthermia. 2007;23:443-50. DOI: 10.1080/02656730701549359.
34. Franckena M, Fatehi D, de Bruijne M, Canters RAM, van Norden Y, Mens JW, Van Rhoon GC, Van Der Zee J. Hyperthermia Dose-Effect Relationship in 420 Patients with Cervical Cancer Treated with Combined Radiotherapy and Hyperthermia. Eur J Cancer. 2009;45(11):1969-78. DOI: 10.1016/j.ejca.2009.03.009.
35. Jones E, Secord AA, Prosnitz LR, Samulski TV, Oleson JR, Berchuck A, Clarke-Pearson D, Soper J, Dewhirst MW., Vujaskovic Z. Intra-Peritoneal Cisplatin and Whole Abdomen Hyperthermia for Relapsed Ovarian Carcinoma. Int J Hyperthermia. 2006;22(2):161–72. DOI: 10.1080/02656730500515270.
36. Milani V, Pazos M, Issels RD, Rahman S, Tschoep K, Schaffer P, Wilkowski R, Duehmke E, Schaffer M. Radiochemotherapy in Combination with Regional Hyperthermia in Preirradiated Patients with Recurrent Rectal Cancer. Strahlentherapie und Onkologie. 2008;184(3):163-68. DOI: 10.1007/s00066-008-1731-8.
37. Ohguri T, Imada H, Kato F, Yahara K, Morioka T, Nakano K, Korogi Y. Radiotherapy with 8 MHz Radiofrequency-Capacitive Regional Hyperthermia for Pain Relief of Unresectable and Recurrent Colorectal Cancer. Int J Hyperthermia. 2006;22(1):1-14.
38. Курпешев О.К., Мардынский Ю.С., Максимов С.А. Комбинированное лечение больных раком полости рта с использованием "условно-динамического" режима фракционирования лучевой терапии и локо-регионарной гипертермии // Сибирское медицинское обозрение. 2011. 1(67). С. 80-84. DOI: 10.1080/02656730500381152. [Kurpeshev OK, Mardynsky YS, Maksimov SA. Combined Treatment of Patients with Oral Cancer Using the "Conditionally Dynamic" Mode of Fractionation of Radiation Therapy and Loco-Regional Hyperthermia. Siberian Medical Review. 2011;67(1):80-4. (In Russ.). DOI: 10.1080/02656730500381152]
39. Курпешев О.К., Андреев В.Г., Панкратов В.А., Гулидов И.А., Орлова А.В. Сравнительные результаты консервативной химиолучевой и термохимиолучевой терапии местнораспространенного рака гортани // Вопросы онкологии. 2014 № 5(60). С. 602-606. [Kurpeshev OK, Andreev VG, Pankratov VA, Gulidov IA, Orlova AV. Comparative Results of Conservative Chemoradiation and Thermochemoradiotherapy of Locally Advanced Laryngeal Cancer. Problems in Oncology. 2014;60(5):602-6. (In Russ.).]
40. Li Z, Sun Q, Huang X, Zhang J, Hao J, Li Y, Zhang S. The Efficacy of Radiofrequency Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Ovarian Cancer. Open Med. 2018;13:83-9. https://doi.org/10.1515/med-2018-0013.
41. Курпешев О.К., Флоровская Н.Ю., Лебедева Т.В. Результаты паллиативной термохимиотерапии метастазов колоректального рака в печень // Вопросы онкологии. 2016. № 1(62). С. 85-90. [Kurpeshev ОК, Florovskaya NY, Lebedeva ТV. Results of Palliative Thermochemotherapy for Colorectal Cancer Metastases to the Liver. Problems in Oncology. 2016;62(1):85-90. (In Russ.).]
42. Yang W-H, Xie J, Lai Z-Y, Yang M-D, Zhang G-H, Li Y, Mu J-B, Xu J. Radiofrequency Deep Hyperthermia Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Chinese Medical J. 2019;132(8):922-7. DOI: 10.1097/CM9.0000000000000156. PMID: 30958433.
43. Maebayashi T, Ishibashi N, Aizawa T, Sakaguchi M, Sato T, Kawamori J, Tanaka Y. Treatment Outcomes of Concurrent Hyperthermia and Chemoradiotherapy for Pancreatic Cancer: Insights into the Significance of Hyperthermia Treatment. Oncology Letters. 2017;13:4959-64.
44. Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, Keck B, Kühn R, Rödel CM, Weiss C, Gall C, Uter W, Fietkau R. Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2). The Oncologist. 2019;24:1–10. www.TheOncologist.com.
45. Ott OJ, Schmidt M, Semrau S, Strnad V, Matzel KE, Schneider I, Raptis D, Uter W, Grützmann R, Fietkau R. Chemoradiotherapy with and without Deep Regional Hyperthermia for Squamous Cell Carcinoma of the Anus. Strahlentherapie und Onkologie. 2019;195(7):607-14. DOI: 10.1007/s00066-018-1396-x
46. Cho C, Wust P, Hildebrandt B, Issels RD, Sehouli J, Kerner T, Deja M, Budach V, Gellermann J. Regional Hyperthermia of the Abdomen in Conjunction with Chemotherapy for Peritoneal Carcinomatosis: Evaluation of Two Annular-Phased-Array Applicators. Int J Hyperthermia. 2008;24(5):399-408. DOI: 10.1080/02656730801929915.
47. Shen H, Li X-D, Wu C-P, Yin Y-M, Wang R-S, Shu Y-Q. The Regimen of Gemcitabine and Cisplatin Combined with Radio Frequency Hyperthermia for Advanced Non-Small Cell Lung Cancer: A Phase II Study. Int J Hyperthermia, February 2011;27(1):27-32. DOI: 10.3109/02656736.2010.500645.
48. Kурпешев O.K., van der Zee J. Анализ результатов рандомизированных исследований по гипертермии в онкологии // Медицинская радиология и радиационная безопасность. 2018. № 3(63). С. 52-67. DOI: 10.12737/article_5b179d60437d54.24079640. [Kurpeshev OK, van der Zee J. Analysis of the Results of Randomized Trials of Hyperthermia in Oncology. Medical Radiology and Radiation Safety. 2018;63(3):52-67. (In Russ.). DOI: 10.12737/article_5b179d60437d54.24079640]
49. Chi MS, Yang KL, Chang YC, Ko H-L, Lin Y-H, Huang S-C, Huang Y-Y, Liao K-W, Kondo M, Chi K-H. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Rad Oncol Biol Phys. 2018;100:78-87. DOI: 10.1016/j.ijrobp.2017.09.030.
50. Li G-X, Lu Z, Sun X-M, Ma C-G., Liu K., Liu J, Guo L, Li P-X. Clinical Effect of Radiofrequency Hyperthermia Combined with Chemotherapy on Stage IV Gastric Cancer. Chinese J. of Cancer Prevention and Treatment. 2010;17:526-28.
51. Fang H, Zhang Y, Wu Z, Wang X, Wang H, Wang Y, Chai F, Jiang Y, Jin Z, Wan Y, Zhu L, Ma S. Regional Hyperthermia Combined with Chemotherapy in Advanced Gastric Cancer. Open Med. 2019;14:85-90. https://doi.org/10.1515/med-2019-0012.
52. Wang Y, Hong W, Che S, Zhang Y, Meng D, Shi F, Su J, Yang Y, Ma H, Liu R, Gao Y, Wang J, Hui B, Wang J, Lu J, Wang T, Liu Z, Chen H. Outcomes for Hyperthermia Combined with Concurrent Radiochemotherapy for Patients with Cervical Cancer. Int J Rad Oncol Biol Phys. Published: March 13, 2020. DOI: 10.1016/j.ijrobp.2020.03.006
53. Datta NR, Pestalozzi B, Clavien P-A, Siebenhüner A, Puric E, Khan S, Mamot C, Riesterer O, Knuchel J, Reiner CS, Bodis S and members of the HEATPAC Trial Group. “HEATPAC J.” – A Phase II Randomized Study of Concurrent Thermochemoradiotherapy Versus Chemoradiotherapy Alone in Locally Advanced Pancreatic Cancer. Radiation Oncology. 2017;12:183. DOI: 10.1186/s13014-017-0923-8.
54. Datta NR, Rogers S, Ordóñez SG, Puric E, Bodis S. Hyperthermia and Radiotherapy in the Management of Head and Neck Cancers: A Systematic Review and Meta-Analysis. Int J Hyperthermia. 2016;32(1):31-40. DOI: 10.3109/02656736.2015.1099746.
55. Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S. Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A SystematicReview and Meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2016; 94:1073-87. DOI: https://doi.org/10.1016/j.ijrobp.2015.12.361.
56. Datta NR, Rogers S, Klingbiel D, Gómez S, Puric E, Bodis S. Hyperthermia and Radiotherapy with or without Chemotherapy in Locally Advanced Cervical Cancer: A Systematic Review with Conventional and Network Meta-Analyses. Int J Hyperthermia. 2016;32(7):809-21. DOI: 10.1080/02656736.2016.1195924.
57. Baoning Q, Chuandao S, Na S, Xinan W, Yuanping H. Efficacy and Safety of Radio-Chemotherapy Combined with Thermotherapy for Advanced Cervical Cancer in Chinese Women: A Meta-Analysis. Arch. Med. Sci. Civil. Dis. 2017;2:e182–e90. DOI: https://doi.org/10.5114/amscd.2017.72542.
58. Hu Y, Li Z, Mi D.-H, Cao N, Zu S-W, Wen Z.-Z, Yu X-L, Qu Y. Chemoradiation Combined with Regional Hyperthermia for Advanced Oesophageal Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Pharmacy and Therapeutics. 2017;42:155-64. DOI: 10.1111/jcpt.12498.
59. Курпешев О.К., Цыб А.Ф., Мардынский Ю.С., Бердов Б.А. Механизмы развития и пути преодоления химиорезистентности опухолей. Часть 3. Возможные пути преодоления химиорезистентности опухолей // Российский онкологический журнал. 2003. № 2. С. 50-52. [Kurpeshev OK, Tsyb AF, Mardynsky YS, Berdov B.A. Mechanisms of development and ways of overcoming the chemoresistance of tumors. Part 3. Possible ways to overcome tumor chemoresistance. Russian Journal of Oncology. 2003;2:50-2. (In Russ).]
60. Курпешев ОК, Van der Zee J. Экспериментальные основы применения гипертермии в онкологии // Медицинская радиология и радиационная безопасность. 2018. № 1(63). С. 57-77. DOI: 10.12737/article_5a8556b4be3e24.36808227. [Kurpeshev OK, Van der Zee J. The Experimental Basis for the Use of Hyperthermia in Oncology. Medical Radiology and Radiation Safety. 2018;63(1):57-77. (In Russ.). DOI: 10.12737/article_5a8556b4be3e24.36808227. (In Russ)]
61. Oei AL, Vriend LEM, Krawczyk PM, Horsman MR, Franken NAP, Crezee J. Targeting Therapy–Resistant Cancer Stem Cells by Hyperthermia. Int J Hyperthermia. 2017;33(4):419-27. DOI: 10.1080/02656736.2017.1279757.
62. Pelicci PG, Dalton P, Orecchia R. Heating Cancer Stem Cells to Reduce Tumor Relapse. Breast Cancer Research. 2011;13:305. DOI: https://doi.org/10.1186/bcr2847.
63. Sakurai H. Tumor Targeting with Hyperthermia. Jpn J Hyperthermic Oncology. 2006;22(2):61-9.
64. Curley SA, Palalon F, Sanders KE, Koshkina NV. The Effects of Non-Invasive Radiofrequency Treatment and Hyperthermia on Malignant and Nonmalignant Cells. Int. J. Environ Res. Public Health. 2014;11(9):9142–53. DOI: 10.3390/ijerph110909142.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The author declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. The article was prepared with equal participatib of authors.
Article received: 18.01.2020. Accepted for publication: 22.05.2021.